Last reviewed · How we verify
Fulvestrant plus Goserelin
Fulvestrant is a selective estrogen receptor degrader that inhibits estrogen receptor-positive breast cancer cell growth, while Goserelin is a gonadotropin-releasing hormone receptor antagonist that suppresses estrogen production.
Fulvestrant is a selective estrogen receptor degrader that inhibits estrogen receptor-positive breast cancer cell growth, while Goserelin is a gonadotropin-releasing hormone receptor antagonist that suppresses estrogen production. Used for Metastatic hormone receptor-positive breast cancer.
At a glance
| Generic name | Fulvestrant plus Goserelin |
|---|---|
| Also known as | Anastrozole plus Goserelin |
| Sponsor | Samsung Medical Center |
| Drug class | Estrogen receptor antagonist and gonadotropin-releasing hormone receptor antagonist |
| Target | Estrogen receptor, Gonadotropin-releasing hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fulvestrant works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting estrogen-dependent breast cancer cell growth. Goserelin, on the other hand, acts on the hypothalamus to suppress the release of gonadotropin-releasing hormone, which in turn reduces the production of estrogen in the ovaries. This dual mechanism of action makes Fulvestrant plus Goserelin a promising treatment for hormone receptor-positive breast cancer.
Approved indications
- Metastatic hormone receptor-positive breast cancer
Common side effects
- Injection site reaction
- Hot flashes
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- Roll-over Study to Allow Continued Access to Ribociclib (PHASE4)
- Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. (PHASE2)
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (PHASE2)
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study (PHASE2)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (PHASE3)
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (PHASE1)
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fulvestrant plus Goserelin CI brief — competitive landscape report
- Fulvestrant plus Goserelin updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI